Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Great-grandparents or cousins with Alzheimer’s linked to higher risk for the disease

Having second-degree or third-degree relatives with Alzheimer’s raises a person’s risk of developing the disease, a new study suggests.

Read More »

Sanofi and Denali Reach Potential $1+ Billion Deal

Denali announced a collaborative deal with Sanofi to develop potential treatments for neurological and systemic inflammatory diseases that could be worth more than $1 billion.

Read More »

Bayer, Orion drug delays spread of prostate cancer

German’s Bayer and Finland’s Orion said a study showed the prostate cancer drug darolutamide that the companies are developing can delay the spread of the disease to other body parts.

Read More »

Startup CuraSen Takes Aim at Parkinson’s and Alzheimer’s

San Mateo, Calif.-based startup CuraSen Therapeutics surged forward with $54.5 million in Series A funding and a leadership team that includes executives from Afferent Pharmaceuticals, a company acquired by Merck in 2016 for $1.2 billion.

Read More »

Elevian Launches to Join Numerous Companies Focused on Longevity and Aging

In another example of companies focused on aging-related diseases, Elevian launched with $5.5 million in seed funding.

Read More »

High Blood Pressure Linked to Brain Lesions and Alzheimer’s in New Research

According to a new study published in Neurology, researchers discovered increased biomarkers for Alzheimer’s in the brains of older patients with high blood pressure, as opposed to those who have average blood pressure readings, CNN reported.

Read More »

Biogen Options Stroke Drug from TMS

Biogen, headquartered in Cambridge, Massachusetts, signed an exclusive option deal with Tokyo-based TMS for TMS-007 and backup compounds.

Read More »

Pfizer to Expand Venture Investing with $600 Million Commitment to Pfizer Ventures

Pfizer Inc. announced plans to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company’s venture investment vehicle.

Read More »

Nature Cell and Biostar Stem Cell Research Institute Begin World’s First Stem Cell-Based Regenerative Treatment for Alzheimer’s Disease in Japan

South Korea’s Biostar Stem Cell Research Institute – jointly operated by Nature Cell and Rbio – announced that Trinity Clinic Fukuoka, a partner hospital in Japan, received approval for the application of regenerative medicine in Alzheimer’s disease and officially began stem cell treatment as of April 12.

Read More »

Alzheon Launches IPO to Fund Alzheimer’s Drug

Alzheon, based in Framingham, Massachusetts, filed with the U.S. Securities and Exchange Commission to launch an initial public offering (IPO).

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!

Subscribe

Ad Right Bottom